144 related articles for article (PubMed ID: 38785199)
1. NR1D1-transactivated lncRNA NUTM2A-AS1 promotes chemoresistance and immune evasion in neuroblastoma via inhibiting B7-H3 degradation.
Xiang T; Li Y; Liu G; Li X
J Cell Mol Med; 2024 May; 28(10):e18360. PubMed ID: 38785199
[TBL] [Abstract][Full Text] [Related]
2. LncRNA ZNF674-AS1 drives cell growth and inhibits cisplatin-induced pyroptosis via up-regulating CA9 in neuroblastoma.
Zhao K; Wang X; Jin Y; Zhu X; Zhou T; Yu Y; Ji X; Chang Y; Luo J; Ni X; Guo Y; Yu D
Cell Death Dis; 2024 Jan; 15(1):5. PubMed ID: 38177154
[TBL] [Abstract][Full Text] [Related]
3. LncRNA NUTM2A-AS1 positively modulates TET1 and HIF-1A to enhance gastric cancer tumorigenesis and drug resistance by sponging miR-376a.
Wang J; Yu Z; Wang J; Shen Y; Qiu J; Zhuang Z
Cancer Med; 2020 Dec; 9(24):9499-9510. PubMed ID: 33089970
[TBL] [Abstract][Full Text] [Related]
4. LncRNA NUTM2A-AS1 aggravates the progression of hepatocellular carcinoma by activating the miR-186-5p/KLF7-mediated Wnt/beta-catenin pathway.
Long J; Liu L; Yang X; Zhou X; Lu X; Qin L
Hum Cell; 2023 Jan; 36(1):312-328. PubMed ID: 36242728
[TBL] [Abstract][Full Text] [Related]
5. Risk-Associated Long Noncoding RNA FOXD3-AS1 Inhibits Neuroblastoma Progression by Repressing PARP1-Mediated Activation of CTCF.
Zhao X; Li D; Huang D; Song H; Mei H; Fang E; Wang X; Yang F; Zheng L; Huang K; Tong Q
Mol Ther; 2018 Mar; 26(3):755-773. PubMed ID: 29398485
[TBL] [Abstract][Full Text] [Related]
6. LncRNA SNHG7 enhances chemoresistance in neuroblastoma through cisplatin-induced autophagy by regulating miR-329-3p/MYO10 axis.
Wang SY; Wang X; Zhang CY
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(7):3805-3817. PubMed ID: 32329857
[TBL] [Abstract][Full Text] [Related]
7. p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance.
Flem-Karlsen K; Tekle C; Øyjord T; Flørenes VA; Mælandsmo GM; Fodstad Ø; Nunes-Xavier CE
Sci Rep; 2019 Apr; 9(1):5839. PubMed ID: 30967582
[TBL] [Abstract][Full Text] [Related]
8. Long Non-Coding RNA NUTM2A-AS1/miR-376a-3p/PRMT5 Axis Promotes Prostate Cancer Progression.
Han H; Li Z; Bi L; Zhang J
Arch Esp Urol; 2024 Mar; 77(2):173-182. PubMed ID: 38583010
[TBL] [Abstract][Full Text] [Related]
9. Silencing of long non-coding RNA DLX6-AS1 weakens neuroblastoma progression by the miR-513c-5p/PLK4 axis.
Jia P; Wei E; Liu H; Wu T; Wang H
IUBMB Life; 2020 Dec; 72(12):2627-2636. PubMed ID: 33031637
[TBL] [Abstract][Full Text] [Related]
10. HNF4A-AS1/hnRNPU/CTCF axis as a therapeutic target for aerobic glycolysis and neuroblastoma progression.
Song H; Li D; Wang X; Fang E; Yang F; Hu A; Wang J; Guo Y; Liu Y; Li H; Chen Y; Huang K; Zheng L; Tong Q
J Hematol Oncol; 2020 Mar; 13(1):24. PubMed ID: 32216806
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma.
Brignole C; Calarco E; Bensa V; Giusto E; Perri P; Ciampi E; Corrias MV; Astigiano S; Cilli M; Loo D; Bonvini E; Pastorino F; Ponzoni M
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37775116
[TBL] [Abstract][Full Text] [Related]
12. Multiparametric flow cytometry highlights B7-H3 as a novel diagnostic/therapeutic target in GD2neg/low neuroblastoma variants.
Dondero A; Morini M; Cangelosi D; Mazzocco K; Serra M; Spaggiari GM; Rotta G; Tondo A; Locatelli F; Castellano A; Scuderi F; Sementa AR; Eva A; Conte M; Garaventa A; Bottino C; Castriconi R
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795387
[TBL] [Abstract][Full Text] [Related]
13. lncRNA NUTM2A-AS1 Targets the SRSF1/Trim37 Signaling Pathway to Promote the Proliferation and Invasion of Breast Cancer.
Ning X; Zhao J; He F; Yuan Y; Li B; Ruan J
Comput Math Methods Med; 2022; 2022():3299336. PubMed ID: 35959349
[TBL] [Abstract][Full Text] [Related]
14.
Chi C; Mao M; Shen Z; Chen Y; Chen J; Hou W
Hum Gene Ther; 2018 Dec; 29(12):1438-1448. PubMed ID: 29896986
[TBL] [Abstract][Full Text] [Related]
15. HOXD-AS1 confers cisplatin resistance in gastric cancer through epigenetically silencing PDCD4 via recruiting EZH2.
Ye Y; Yang S; Han Y; Sun J; Xv L; Wu L; Ming L
Open Biol; 2019 Sep; 9(9):190068. PubMed ID: 31551012
[TBL] [Abstract][Full Text] [Related]
16. LncRNA FOXD2-AS1 knockdown inhibits the resistance of human osteosarcoma cells to cisplatin by inhibiting miR-143 expression.
Zhang QQ; Xu SL; Ding C; Ma CC; Yuan TS; Hua CC; Wang XH
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(2):678-686. PubMed ID: 33577022
[TBL] [Abstract][Full Text] [Related]
17. The LncRNA FGD5-AS1/miR-497-5p axis regulates septin 2 (SEPT2) to accelerate cancer progression and increase cisplatin-resistance in laryngeal squamous cell carcinoma.
Song K; Yu P; Zhang C; Yuan Z; Zhang H
Mol Carcinog; 2021 Jul; 60(7):469-480. PubMed ID: 34003510
[TBL] [Abstract][Full Text] [Related]
18. Proteomic Signature of Neuroblastoma Cells UKF-NB-4 Reveals Key Role of Lysosomal Sequestration and the Proteasome Complex in Acquiring Chemoresistance to Cisplatin.
Merlos Rodrigo MA; Buchtelova H; de Los Rios V; Casal JI; Eckschlager T; Hrabeta J; Belhajova M; Heger Z; Adam V
J Proteome Res; 2019 Mar; 18(3):1255-1263. PubMed ID: 30592607
[TBL] [Abstract][Full Text] [Related]
19. Astragaloside IV Enhances Cisplatin Chemosensitivity in Non-Small Cell Lung Cancer Cells Through Inhibition of B7-H3.
He CS; Liu YC; Xu ZP; Dai PC; Chen XW; Jin DH
Cell Physiol Biochem; 2016; 40(5):1221-1229. PubMed ID: 27960166
[TBL] [Abstract][Full Text] [Related]
20. H3K27ac-activated LncRNA NUTM2A-AS1 Facilitates the Progression of Colorectal Cancer Cells via MicroRNA-126-5p/FAM3C Axis.
Lin H; Hu S; Li Y; Li S; Teng D; Yang Y; Liu B; Du X
Curr Cancer Drug Targets; 2024 Feb; ():. PubMed ID: 38347779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
